Parameters | RCB-TILs in all breast cancers (n = 177) | p value | |
---|---|---|---|
Positive (n = 112) | Negative (n = 65) | ||
Age at operation | |||
≤ 56 | 52 (46.4%) | 35 (53.9%) | |
> 56 | 60 (53.6%) | 30 (46.1%) | 0.341 |
Menopause | |||
Pre-menopausal | 44 (39.3%) | 28 (43.1%) | |
Post-menopausal | 68 (60.7%) | 37 (56.9%) | 0.621 |
Tumor size | |||
≤ 2 cm | 19 (17.0%) | 5 (7.7%) | |
> 2 cm | 93 (83.0%) | 60 (92.3%) | 0.082 |
Lymph node status | |||
Negative | 27 (24.1%) | 14 (21.5%) | |
Positive | 85 (75.9%) | 51 (78.5%) | 0.696 |
Nuclear grade | |||
1, 2 | 81 (72.3%) | 56 (86.2%) | |
3 | 31 (27.7%) | 9 (13.8%) | 0.034 |
Ki67 | |||
≤ 14% | 36 (32.1%) | 38 (58.5%) | |
> 14% | 76 (67.9%) | 27 (41.5%) | 0.001 |
Intrinsic subtype | |||
TNBC | 49 (43.8%) | 12 (16.0%) | |
non-TNBC | 63 (56.2%) | 53 (84.0%) | 0.001 |
Intrinsic subtype | |||
HER2BC | 26 (23.2%) | 10 (15.4%) | |
non- HER2BC | 86 (76.8%) | 55 (84.6%) | 0.212 |
Intrinsic subtype | |||
HRBC | 37 (33.0%) | 43 (66.2%) | |
non-HRBC | 75 (67.0%) | 22 (33.8%) | <0.001 |
Pathological response | |||
pCR | 58 (51.8%) | 9 (13.8%) | |
non-pCR | 54 (48.2%) | 56 (86.2%) | <0.001 |